2026年，丹麦制药巨头诺和诺德的明星减重药司美格鲁肽核心分子在中国的专利即将到期，届时，该药物将面临大量来自中国仿制药的竞争。在这一背景下，诺和诺德正在积极推动口服版司美格鲁肽减重药在全球的上市进程。近日，诺和诺德在《新英格兰医学杂志》（NEJM）上发表一项最新三期临床数据，试验评估了在研的每日一次口服司美格鲁肽片（25mg片剂）的有效性和安全性。结果显示，在服药64周时，口服司美格鲁肽片...
Source Link2026年，丹麦制药巨头诺和诺德的明星减重药司美格鲁肽核心分子在中国的专利即将到期，届时，该药物将面临大量来自中国仿制药的竞争。在这一背景下，诺和诺德正在积极推动口服版司美格鲁肽减重药在全球的上市进程。近日，诺和诺德在《新英格兰医学杂志》（NEJM）上发表一项最新三期临床数据，试验评估了在研的每日一次口服司美格鲁肽片（25mg片剂）的有效性和安全性。结果显示，在服药64周时，口服司美格鲁肽片...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.